Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) insider Robert Berman sold 25,845 shares of the business’s stock in a transaction dated Thursday, June 7th. The shares were sold at an average price of $36.01, for a total transaction of $930,678.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Robert Berman also recently made the following trade(s):

  • On Tuesday, June 12th, Robert Berman sold 104,155 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $36.33, for a total value of $3,783,951.15.
  • On Tuesday, June 5th, Robert Berman sold 6,362 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $36.02, for a total value of $229,159.24.
  • On Thursday, May 10th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $26.82, for a total value of $938,700.00.
  • On Tuesday, April 10th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $24.66, for a total value of $863,100.00.
  • On Monday, March 12th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $30.11, for a total value of $1,053,850.00.

Shares of NYSE:BHVN traded up $1.07 during trading on Thursday, reaching $39.65. 349,300 shares of the stock were exchanged, compared to its average volume of 607,199. Biohaven Pharmaceutical Holding Co Ltd has a 12-month low of $16.50 and a 12-month high of $39.69. The stock has a market capitalization of $1.40 billion and a P/E ratio of -7.88.

Biohaven Pharmaceutical (NYSE:BHVN) last issued its earnings results on Tuesday, May 15th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.12) by ($1.20). research analysts expect that Biohaven Pharmaceutical Holding Co Ltd will post -6.77 EPS for the current year.

BHVN has been the subject of several recent analyst reports. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a report on Friday, March 9th. Barclays cut Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $30.00 to $25.00 in a report on Thursday, April 5th. Piper Jaffray Companies set a $48.00 price target on Biohaven Pharmaceutical and gave the company a “buy” rating in a report on Friday, June 8th. Canaccord Genuity reiterated a “buy” rating and set a $39.00 target price (up previously from $30.00) on shares of Biohaven Pharmaceutical in a report on Thursday, February 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $36.00 target price on shares of Biohaven Pharmaceutical in a report on Wednesday, May 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $37.43.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BHVN. BlackRock Inc. boosted its holdings in Biohaven Pharmaceutical by 63.6% in the 1st quarter. BlackRock Inc. now owns 1,888,608 shares of the company’s stock worth $48,650,000 after acquiring an additional 734,401 shares during the period. Alliancebernstein L.P. boosted its holdings in Biohaven Pharmaceutical by 84.9% in the 4th quarter. Alliancebernstein L.P. now owns 1,597,756 shares of the company’s stock worth $43,107,000 after acquiring an additional 733,526 shares during the period. Carillon Tower Advisers Inc. purchased a new position in Biohaven Pharmaceutical in the 4th quarter worth approximately $18,627,000. Foresite Capital Management IV LLC boosted its holdings in Biohaven Pharmaceutical by 298.8% in the 1st quarter. Foresite Capital Management IV LLC now owns 851,200 shares of the company’s stock worth $21,927,000 after acquiring an additional 637,765 shares during the period. Finally, Millennium Management LLC purchased a new position in Biohaven Pharmaceutical in the 4th quarter worth approximately $7,459,000. Hedge funds and other institutional investors own 77.29% of the company’s stock.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.